<DOC>
	<DOCNO>NCT02130648</DOCNO>
	<brief_summary>The purprose study develop validate analytical clinical NIPD test cystic fibrosis maternal blood analysis circulate free fetal DNA ( cff-DNA ) , search paternal mutation family CFTR compound heterozygosity</brief_summary>
	<brief_title>Non Ivasive Prenatal Diagnosis ( NIPD ) Cystic Fibrosis</brief_title>
	<detailed_description>The recent development technique analyze foetal DNA circulate blood maternal open new perspective prenatal diagnosis ( PD ) . Non-invasive PND ( NIPD ) method choice determination fetal sex ( genetic disorder link X chromosome ) rhesus genotype . NIPD begin find application diagnosis monogenic disease mutation paternal transmission . However number technical challenge still hamper diagnostic application routine , resolve take account aspect cost , reliability ( false negative .. ) complexity equipment bioinformatics study . The investigator propose develop validate analytical clinical NIPD test cystic fibrosis maternal blood analysis circulate free fetal DNA ( cff-DNA ) , search paternal mutation family CFTR compound heterozygosity . The test method base MEMO associated platform real-time PCR use detection trace DNA mutant . This technique commonly use mutation mosaic ( le 1 % ) gene common cancer . Positive detection paternal mutation always check second mini-sequencing technique . Prior specific CFTR test , DNA profile sample determine use commercial kit Mini STR adapt study casework . A tri-allelic profile marker prove presence fetal DNA study specimen thus limit false negative associate lack insufficient amount cff-DNA . The validation step investigator analytical method make chimeric DNA control sample artificially create . Then test clinicaly validate retrospective study maternal serum pregnant woman , subject PND PGD ( preimplantation genetic diagnosis ) CF request laboratory study period ( 2012 2013 ) . The investigator structure reference center PGD , PND NBS ( newborn screening ) cystic fibrosis . The sample collect accordance current regulations.The pre-analytical sample treatment do real time plasma store second step study . The validation propose test permit : - To external quality control ( QC ) confirm presence minor DNA study sample . This QC could use NIPD test base search genomic sequence absent maternal genome - To highly sensitive method detect trace mutant DNA develop new NIPD test monogenic disease detect mutation nature . The investigator project , limited search paternal allele family CFTR compound heterozygosity , first step implementation prenatal diagnosis approach cystic fibrosis investigator aim develop order reduce invasive procedure .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<criteria>Inclusion criterion : pregnant woman risk cystic fibrosis foetus Exclusion criterion : parent CF mutant allele</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Non-invasive Prenatal Diagnosis ( NIPD )</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Quantitative real time MEMO-PCR</keyword>
</DOC>